BioCentury
ARTICLE | Company News

Oxford BioTherapeutics, Menarini deal

November 5, 2012 8:00 AM UTC

Oxford partnered with Menarini to develop five of Oxford's antibody and antibody-drug conjugate (ADC) programs for undisclosed cancer indications. Oxford will provide undisclosed targets, antibodies and "arming technologies." Menarini will be responsible for the manufacture and clinical development of each program through proof-of-concept, which will be determined for each program. After POC, Oxford will develop the programs in North America and Japan, while Menarini will develop them in Europe, the Commonwealth of Independent States (CIS), Asia and Latin America. The companies will have commercialization rights in the territories where they develop the programs. ...